TSO3 (TSE:TOS)‘s stock had its “buy” rating reiterated by equities researchers at Echelon Wealth Partners in a research report issued on Wednesday.
A number of other equities analysts have also recently commented on the stock. National Bank Financial reaffirmed a “sector perform” rating and set a C$1.25 price target on shares of TSO3 in a research note on Thursday, December 20th. Royal Bank of Canada decreased their target price on shares of TSO3 from C$0.90 to C$0.80 and set a “sector perform” rating on the stock in a research report on Thursday, November 8th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of C$1.58.
TOS opened at C$0.64 on Wednesday. TSO3 has a fifty-two week low of C$0.35 and a fifty-two week high of C$2.74. The company has a quick ratio of 7.26, a current ratio of 9.07 and a debt-to-equity ratio of 415.90.
TSO3 Company Profile
TSO3 Inc engages in the research, development, production, maintenance, sale, and licensing of sterilization processes, related consumable supplies, and accessories for heat and moisture sensitive medical devices worldwide. Its principal product is the STERIZONE VP4 sterilizer, a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide and ozone that is marketed in Canada and the United States.
Featured Article: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for TSO3 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TSO3 and related companies with MarketBeat.com's FREE daily email newsletter.